Latest News and Press Releases
Want to stay updated on the latest news?
-
Oslo, Norway, 19th of August 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the second quarter 2022 Revenue in second quarter ended at MNOK 69...
-
Oslo, Norway, 11 August 2022 Vistin Pharma ASA will release its second quarter and YTD 2022 results on Friday 19th of August 2022. Vistin Pharma will host a conference call for all shareholders...
-
Oslo, Norway, 19 May 2022 Vistin Pharma ASA (OSE: VISTIN), please find attached the minutes from the annual general meeting held on 19 May 2022. All matters were resolved as proposed in the call for...
-
Oslo, Norway, 28 April 2020 Vistin Pharma ASA (OSE: VISTIN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 19 May at 10:00 CEST. A physical...
-
Oslo, Norway, 27 April 2022 Please find attached the Annual Report for 2021 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full...
-
Oslo, Norway, 27th of April 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter 2022 Revenue in first quarter ended at MNOK 33 compared...
-
Oslo, Norway, 20 April 2022 Vistin Pharma ASA will release its first quarter 2022 results on Wednesday 27th of April 2022. Vistin Pharma will host a conference call for all shareholders and...
-
Oslo, Norway, 17th of February 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the fourth quarter 2021 Revenue in fourth quarter ended at MNOK 78...
-
CEO Kjell-Erik Nordby is currently on sick-leave, and the Board in Vistin Pharma, with effect from today, has appointed Magnus Tolleshaug as interim CEO. Magnus Tolleshaug has been employed in Vistin...
-
Oslo, Norway, 8 February 2022 Vistin Pharma ASA will release its fourth quarter 2021 results on Thursday 17th of February 2022. Vistin Pharma will host a conference call for all shareholders and...